Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) has shared an announcement.
Haleon PLC announced a share buyback transaction, purchasing 1,016,186 ordinary shares for cancellation under its buyback program. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, which may impact voting rights and shareholding notifications under regulatory rules.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score is bolstered by strong financial performance and positive earnings guidance, which are the most significant factors. The strategic share buybacks further enhance shareholder value. However, technical indicators suggest bearish momentum, and the valuation is relatively high, posing potential risks.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse product portfolio across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, which are built on a foundation of science, innovation, and deep human understanding.
Average Trading Volume: 24,854,396
Technical Sentiment Signal: Buy
Current Market Cap: £34.56B
Learn more about HLN stock on TipRanks’ Stock Analysis page.